Rivaroxaban plus aspirin increases major bleeding in patients with chronic CAD, PAD
Patients with chronic coronary (CAD) or peripheral artery disease (PAD) treated with the combination of rivaroxaban and aspirin are at greater risk of bleeding than those treated with aspirin alone, according to a study. Major bleeding usually occurs during the first year of treatment, arises in the gastrointestinal (GI) tract and can be managed using conventional supportive therapies.
Rivaroxaban plus aspirin increases major bleeding in patients with chronic CAD, PAD
23 Sep 2019